Deputy Manager & PMO Coordinator
About the job
- Excellent understanding of project management processes related to pharmaceutical discovery, development, and manufacturing from project initiation to closeout.
- Ability to work independently and stay on task while working remotely.
- Strong communication skills and excellent command of English to interact effectively with stakeholders across multiple time zones.
- Strong presentation skills with the ability to present interactively and engage listeners in a two-way conversation.
- Personal initiative, persuasiveness, assertiveness, and a collaborative approach.
- Results-oriented ability to translate process and user requirements into a solution.
- Extremely strong technology proficiency and the ability to learn new systems quickly.
- Coordinate with Global Project Management Office team members to support ongoing initiatives.
- Attend and track participation in monthly Global Project Management team meetings.
- Maintain the new Project Manager onboarding process.
- Issue Project Workspaces and maintain the PMO Coordinator Manual.
- Own the continued development and maintenance of the Project Management intranet site.
- Develop and maintain Project Management process maps and training curricula supporting those process maps.
- Manage the monthly change-order review and reporting process.
- Organize meetings with Global Project Managers and key stakeholders to gather process input for creating process maps.
- Collect and maintain metrics for all Global Project Managers, including global meeting attendance and participation.
- Create training content accompanying Project Management processes with support from the Learning and Development team and Global PMO members.
- Create and manage Global Project Management intranet content, including researching industry news and client information and collaborating with sites on site-specific content.
- Provide regular stakeholder updates and present project status and progress to senior leadership.
- Proximity to an existing Piramal site.
- Experience with Smartsheet, Microsoft Office applications, Qlik Sense, or another business intelligence tool.
About the company
Piramal Pharma operates through three divisions: Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and the Consumer Products Division (CPD). PPS acts as a contract development and manufacturing organization (CDMO), offering development and manufacturing services across the drug lifecycle for clients in North America, Europe, and Asia. PCC specializes in complex hospital generics, especially inhaled anesthetics, serving the USA, Europe, and more than 100 countries. CPD markets consumer health brands in India, including Littles, Lacto Calamine, i-pill, Tetmosol, Polycrol, and Tri Activ, and aims to provide reliable development, manufacturing, and distribution capabilities to meet customer needs.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
N/A
Headquarters
India
Founded
2020
Get referred to Piramal Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- Yapan Bio became a subsidiary on August 18, 2026, strengthening biologics and vaccines.
- Kenalog supply starts in Q2FY27, adding $30-40 million annualized revenue.
- Morpeth solar begins Q1 2027, cutting Scope 1 and 2 emissions 42% by FY2030.
What critics are saying
- FDA issued a Form 483 with seven observations at Morpeth on September 14, 2026.
- Q1 FY27 revenue fell 17.5%; inventory destocking and weak early-stage CDMO inflows persist.
- If Morpeth remediation slips, UK supply, customer trust, and CDMO wins stall into 2027.
What makes Piramal Pharma unique
- Piramal spans CDMO, hospital generics, and Indian consumer healthcare across 100+ countries.
- PPS offers ADCs, sterile fill-finish, peptides, and biologics through Yapan Bio.
- Kenalog and inhaled anesthetics give Piramal harder-to-replicate niche products and hospital channels.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Stock Options
Growth & Insights and Company News
6 month growth
11%1 year growth
11%2 year growth
17%Viral Gandhi elevated to Chief Technology Officer at Piramal Pharma. With more than three decades of experience in the technology industry, Viral Gandhi brings extensive expertise in enterprise IT, technology strategy, digital transformation and global technology delivery to the new role. Published on: 07 Oct 2026, 11:03 pm Piramal Pharma Limited has elevated Viral Gandhi to the position of Chief Technology Officer (CTO) and Senior Management Personnel, effective October 1, 2026. The elevation was approved by the company's Board of Directors on September 30, 2026. Prior to this elevation, Viral Gandhi was serving as President and Group Chief Information Officer of Piramal Group, where he was responsible for driving technology innovation and digital-led transformation across the Group's entities. With more than three decades of experience in the technology industry, Viral Gandhi brings extensive expertise in enterprise IT, technology strategy, digital transformation and global technology delivery to the new role. New Technology Leadership Role As President and Group CIO, Viral Gandhi led group-wide technology initiatives and worked on enabling Piramal Group's businesses to leverage technology and digital platforms to strengthen operations and stakeholder engagement. The role involved driving technology innovation and developing digital capabilities aligned with business objectives. The elevation to CTO at Piramal Pharma expands Viral Gandhi's technology leadership responsibilities as the company continues to strengthen its digital capabilities, technology infrastructure and technology-led business initiatives. Leadership Experience Spans Multiple Industry Sectors Viral Gandhi has held senior technology responsibilities within the Piramal Group, where he has led group-wide IT initiatives and contributed to the organisation's technology and digital transformation agenda. Before joining Piramal Group, Viral Gandhi served as Chief Information Officer at Cox & Kings Group, where he was involved in driving technology strategy and transformation initiatives across the group's businesses and global operations. Earlier in his career, Viral Gandhi worked with Tata Consultancy Services (TCS), progressing through roles including Project Manager, IT Delivery Manager and IT Delivery Head. During his tenure, he managed global teams and technology programmes and worked with several Fortune 100 organisations, including General Electric, NASDAQ, World Bank, HP and Procter & Gamble. Strong Track Record in Enterprise Technology Viral Gandhi is a technology and digital strategist with experience in developing and implementing technology solutions, driving digital transformation and building technology-focused organisational cultures. His career spans enterprise IT, technology strategy, global service delivery and business transformation. Viral Gandhi has also received several awards and recognitions for contributions to technology and innovation. His academic credentials include an Executive Leadership Program from Harvard Business School in the US and a Strategy and Innovation Program from the Massachusetts Institute of Technology (MIT). Viral Gandhi holds a Bachelor's degree in Engineering from VJTI, Mumbai. With the elevation, Viral Gandhi takes on an expanded technology leadership mandate at Piramal Pharma, bringing more than 25 years of experience to the company's technology and digital transformation agenda. [Stay informed with our latest updates by joining the] [WhatsApp Channel now!]
Piramal Pharma share price in focus; Bayer sales and distribution deal to end on December 31. Piramal Pharma's sales and distribution arrangement with Bayer will end on December 31, 2026, with no renewal planned. Piramal Pharma's existing commercial arrangement with Bayer Pharmaceuticals will come to an end at the close of December. The company said the arrangement, under which it provides sales and distribution support to Bayer, will not be renewed after its current term. The agreement will continue until December 31, 2026. Piramal Pharma and Bayer are also working through the activities covered under the arrangement to ensure the transition is completed smoothly. Arrangement based on distribution support. Under the agreement, Piramal Pharma handled sales and distribution support for Bayer and received commission-based income for the services. The company has not disclosed the exact amount of commission earned from the arrangement. It said the revenue linked to the business contributes less than 5% of its consolidated revenue. Piramal Pharma sees limited financial impact. Piramal Pharma said it does not expect the non-renewal to have a material impact on its profitability or financial position. The company linked this assessment to the size and nature of the arrangement, noting that the income was commission-based. Bayer arrangement ends after current term. There is no immediate change to the existing arrangement. It remains in place through December 31, after which the commercial relationship covered by the agreement will conclude. Piramal Pharma share price performance. As of 01 October 2026, Piramal Pharma Ltd share price closed at ₹198.30 per share, reflecting a decline of 3.98% from the previous trading session. Conclusion. Piramal Pharma's Bayer distribution arrangement will expire at the end of 2026 and will not continue into a new term. With the related revenue accounting for less than 5% of consolidated revenue, the company has said it does not expect the change to materially affect its financial position or profitability. Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. Investments in the securities market are subject to market risks, read all the related documents carefully before investing. Published on: Oct 2, 2026, 4:39 PM IST Team Angel One Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories. Open free demat account! Join its 3.8 Cr+ happy customers 10 Cr+ DOWNLOADS Enjoy ₹0 account opening charges. Get the link to download the App
Ont. government invests $1.7M in Piramal Pharma Solutions' Aurora, ont. facility. October 1, 2026 by CM Staff With support from the government of Ontario, Piramal Pharma is also reportedly investing $5,314,000 to upgrade site infrastructure at their Aurora facility, strengthening Ontario's pharmaceutical manufacturing and bolstering the company's production capabilities. Talking points. Piramal Pharma Solutions (PPS) has secured a $1,753,620 investment from the Ontario government via the Life Sciences Scale-Up Fund to enhance its Aurora drug substance site. This funding will enable upgrades to infrastructure and support the commercialization of Ontario-made health technologies. The investment will also see PPS contribute $5,314,000 to bolster its production capabilities, creating 12 new jobs while safeguarding 183 existing positions. CEO Peter DeYoung emphasized the importance of this funding for advancing sustainability and operational efficiency at the facility. * The Life Sciences Scale-Up Fund aims to strengthen Ontario's pharmaceutical manufacturing sector. * Piramal's project will enhance R&D and clinical API production in the province. * The initiative aligns with Ontario's broader Life Sciences Strategy to boost local innovation. This investment is significant for Ontario's economy, reinforcing its status as a global hub for biomanufacturing and life sciences while fostering job creation and technological advancement. Powered by: MUMBAI - Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., announced that its Aurora, Canada drug substance site has received a $1,753,620 investment from the Ontario government through the Life Sciences Scale-Up Fund (LSSUF), enabling PPS to upgrade site infrastructure and commercialize Ontario-made health technologies for new markets. With support from the government of Ontario, Piramal Pharma is also reportedly investing $5,314,000 to upgrade site infrastructure at their Aurora facility, strengthening Ontario's pharmaceutical manufacturing and bolstering the company's production capabilities. This project will reportedly enhance R&D and clinical API production in Ontario as well. The company reports that the investment will "create 12 new jobs and protect 183 existing positions." "We are grateful to the Government of Ontario and MPP Dawn Gallagher Murphy for their support of this important investment in our Aurora facility," said Peter DeYoung, CEO, Piramal Global Pharma. "This funding will help enable Piramal Pharma Solutions to upgrade our site infrastructure, strengthen our manufacturing capabilities, and enhance our ability to serve patients and customers around the world. In addition to supporting business growth, this investment will help advance projects focused on sustainability, operational efficiency, and the modernization of our site, reinforcing our commitment to responsible manufacturing and environmental stewardship." "Through the Life Sciences Scale-Up Fund, our government is ensuring that Ontario businesses are positioned to develop, commercialize and deploy new technologies across the health-care system," said Dawn Gallagher Murphy, Member of Provincial Parliament for Newmarket-Aurora. "With this investment, Piramal will be positioned to turn their latest ideas into market-ready solutions, all while creating good-paying jobs and reinforcing Ontario's position as a global biomanufacturing and life sciences hub." First launched in 2024, the $24 million LSSUF works in tandem with the government's Health Innovation Pathway to try and advance the objectives of Phase 2 of Ontario's Life Sciences Strategy and strengthen Ontario's position as a pharmaceutical manufacturer. "Ontario's life sciences sector plays a critical role in supporting the discovery and development of innovative medicines and technologies, which is why our government is proud to support local companies as they take their Ontario-made products to the next level," said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. "By investing in Piramal through the Life Sciences Scale-Up Fund, we are scaling up our province's domestic capacity while further positioning Ontario as a leading jurisdiction for life sciences investment for generations to come."
Piramal Pharma Solutions advances sustainability efforts with solar power plant addition at Morpeth, UK site. Sep 16, 2026, 10:14 ET * Piramal Pharma Solutions is installing a ground-mounted solar power plant (4.3 MWp) at its integrated drug substance and drug product site in Morpeth, UK. * The new plant will provide renewable energy directly to the site through a behind-the-meter setup, supporting Piramal's commitment to reduce Scope 1 and Scope 2 greenhouse gas emissions by 42% by FY2030. MUMBAI, India, Sept. 16, 2026 /CNW/ - Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA) (BSE: 543635), is strengthening its decarbonization efforts with the addition of a 4.3 MWp ground-mounted solar power plant at its integrated drug substance and drug product facility in Morpeth, UK. Once operational, the plant will supply the site with approximately 3,950 MWh of renewable electricity each year, meeting around 22% of its annual electricity demand. Featuring around 6,200 solar panels across 16 acres of land, the installation will produce enough clean energy to power approximately 1,460 UK homes per year. The project is being delivered under a Power Purchase Agreement (PPA) with Alight UK BTM1 Limited ("Alight"), a leading solar developer and independent power producer. This initiative will enable Morpeth to avoid an estimated 20,000 tCO[2]e over 25 years, marking a significant step forward in PPL's sustainability journey and long-term decarbonization strategy. By implementing a sustainable, cost-effective solution for onsite electricity generation, PPL is enhancing the resilience of its energy supply while demonstrating its commitment to a lower-carbon future. "At Piramal Pharma Solutions, we integrate sustainability principles into every operation and decision across our global network," said Frank Bugg, Senior Vice President, UK & Europe Operations and Managing Director, Piramal Pharma Solutions. "We are excited to advance our commitment to decarbonization and renewable energy with our partner Alight, bringing new value to our customers and shareholders worldwide." "Businesses across the UK are looking for practical ways to lower emissions, strengthen energy resilience, and manage long-term energy costs. This project with Piramal Pharma shows how onsite solar can deliver all three," says Rob Stait, Managing Director, Behind the Meter at Alight. Project operations are scheduled to begin in the first quarter of 2027. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. SOURCE Piramal Pharma Solutions For Investor Queries: Gagan Borana | Investor Relations & Enterprise Risk Management | [email protected], For Media Queries: Madiha Vahid | Lead - Branding & Communications | [email protected]
Piramal Pharma Limited completes acquisition of controlling stake in Yapan Bio Private Limited. Aug 18, 2026, 15:36 ET * Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. * Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing. * This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services. MUMBAI, India, Aug. 18, 2026 /PRNewswire/ - Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ("Yapan Bio"), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL. Finalized on August 18, 2026, the acquisition marks a major step forward in PPL's long-range plan to expand its presence in the biologics sector. With the finalization of this deal, PPL will fully embed the subsidiary's advanced large molecule capabilities into its integrated service offering, enabling the Company to offer customers broader services in the space and expanding its ability to develop and scale complex biologic therapies with greater efficiency. The subsidiary will continue to operate within the structure of Piramal Pharma Solutions (PPS), the CDMO arm of PPL. Yapan Bio also directly supports ADCelerate(TM)- PPS's fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further enhances ADCelerate(TM) and reinforces PPL's ability to deliver life-saving ADCs to market with speed and consistency. "This strategic investment doesn't just fuel our long-term growth; it also puts Patient Centricity into action," said Peter DeYoung, CEO, Piramal Global Pharma. "By integrating Yapan Bio's specialized expertise into our global network, we're empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need." About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited. About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. SOURCE Piramal Pharma Solutions